Breaking Down SG&A Expenses: Bio-Techne Corporation vs Supernus Pharmaceuticals, Inc.

SG&A Expenses: Bio-Techne vs Supernus Pharmaceuticals

__timestampBio-Techne CorporationSupernus Pharmaceuticals, Inc.
Wednesday, January 1, 20146071600072471000
Thursday, January 1, 201511940100089204000
Friday, January 1, 2016140879000106010000
Sunday, January 1, 2017199243000137905000
Monday, January 1, 2018240636000159888000
Tuesday, January 1, 2019264359000158425000
Wednesday, January 1, 2020260583000200677000
Friday, January 1, 2021324951000304759000
Saturday, January 1, 2022372766000377221000
Sunday, January 1, 2023378378000336361000
Monday, January 1, 2024396826000
Loading chart...

Igniting the spark of knowledge

A Comparative Analysis of SG&A Expenses in the Biotech Sector

In the ever-evolving biotech industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Bio-Techne Corporation and Supernus Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Bio-Techne's SG&A expenses surged by over 550%, peaking in 2024, while Supernus Pharmaceuticals saw a 360% increase, reaching its zenith in 2022.

Bio-Techne consistently outpaced Supernus in SG&A spending, reflecting its aggressive growth strategy. Notably, in 2022, Supernus briefly surpassed Bio-Techne, highlighting a strategic shift. However, by 2023, Bio-Techne regained its lead, underscoring its robust market position. The data for 2024 shows a gap for Supernus, indicating potential strategic realignments or reporting delays. This financial snapshot offers a window into the strategic priorities and market positioning of these biotech giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025